Pneumococcal and meningococcal group C vaccine conjugate - Wyeth

Drug Profile

Pneumococcal and meningococcal group C vaccine conjugate - Wyeth

Alternative Names: Meningococcal group C and pneumococcal vaccine conjugate - Wyeth Vaccines

Latest Information Update: 17 Aug 2009

Price : $50

At a glance

  • Originator Wyeth
  • Class Meningococcal vaccines; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Meningococcal group C infections; Pneumococcal infections

Most Recent Events

  • 05 Nov 2003 Data presented at the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA-2003) have been added to the Viral infections immunogenicity section
  • 31 Dec 2002 Phase-III clinical trials in Pneumococcal infections in USA (IM)
  • 31 Dec 2002 Phase-III clinical trials in Meningococcal group C infections in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top